$PHVS
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Healthcare
Sector
Biotechnology
Industry
Berndt Axel Edvard Modig
CEO
108
Employees
$32.21
Current Price
$1.63B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 10 | 16 | $19,424,687.43 | 534,210 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 10 | 19 | $20,414,903.17 | 559,502 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 10 | 20 | $20,495,057.62 | 561,794 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Monges Viviane Director | Sale | 11,969 | $33.05 | $395,523.98 | View Details |
| Sep 22, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale | 800 | $36.19 | $28,952.00 | View Details |
| Sep 21, 2026 | Nassif David W. CFO / CLO | Sale | 6,000 | $36.47 | $218,800.80 | View Details |
| Sep 17, 2026 | Lu Peng President | Sale | 100,000 | $35.00 | $3,500,000.00 | View Details |
| Sep 17, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale | 200,000 | $35.00 | $7,000,000.00 | View Details |
| Sep 17, 2026 | Bjork Elisabeth Director | Sale | 52,500 | $37.89 | $1,989,408.75 | View Details |
| Sep 17, 2026 | Glassman Robert Director | Sale | 14,493 | $38.56 | $558,812.40 | View Details |
| Sep 17, 2026 | Lesage Anne Chief Early Development | Sale | 20,000 | $38.27 | $765,466.00 | View Details |
| Sep 15, 2026 | Abele Stefan Andreas Chief Technical Ops Officer | Sale | 1,400 | $39.24 | $54,937.54 | View Details |
| Sep 15, 2026 | Abele Stefan Andreas Chief Technical Ops Officer | Sale | 45,000 | $38.14 | $1,716,187.50 | View Details |
| Sep 15, 2026 | Glassman Robert Director | Sale | 8,667 | $38.27 | $331,716.42 | View Details |
| Sep 15, 2026 | Souverijns Wim Chief Commercial Officer | Sale | 6,090 | $38.99 | $237,449.10 | View Details |
| Sep 14, 2026 | Souverijns Wim Chief Commercial Officer | Sale | 20,000 | $39.31 | $786,126.00 | View Details |
| Sep 11, 2026 | Lu Peng President | Sale | 15,000 | $40.13 | $601,947.00 | View Details |
| Sep 14, 2026 | Modig Berndt Director | Sale | 2,291 | $39.40 | $90,275.94 | View Details |
| Sep 10, 2026 | Lesage Anne Chief Early Development | Sale | 30,000 | $38.30 | $1,149,084.00 | View Details |
| Sep 9, 2026 | Glassman Robert Director | Sale | 8,000 | $37.55 | $300,396.00 | View Details |
| Sep 8, 2026 | Lu Peng President | Sale | 15,000 | $40.68 | $610,134.00 | View Details |
| Aug 14, 2026 | Modig Berndt Director | Sale | 2,292 | $34.77 | $79,685.73 | View Details |
| Jul 13, 2026 | Modig Berndt Director | Sale | 2,292 | $34.97 | $80,154.45 | View Details |
51 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.